Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (<i>nab</i>-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).Douglas R. Adkins, D. I. Kuperman, Hiram A. Gay et al.|Journal of Clinical Oncology|2011Cited by 6
Safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (<i>nab</i>-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in 30 patients (pts) with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).D. I. Kuperman, Douglas R. Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2011Cited by 3
Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).Jessica Ley, D. Adkins, D. I. Kuperman et al.|Journal of Clinical Oncology|2011Cited by 0